Clene Inc.’s Chidozie Offloads 3,938 Shares at $6.29 After Prior $6.03 Sale
On January 7, 2026, Clene Inc. director Ugwumba Chidozie sold 3,938 shares at $6.29 each, following a December 30 sale of 4,138 shares at $6.03, reducing his holdings to 753,562 shares valued at approximately $4.7 million. Shares traded between $6.06 and $6.56 on that day, climbing 2.28%.
1. Oversubscribed Registered Direct Offering Secures Over $28 Million
Clene Inc. announced the successful pricing of a registered direct offering that raised more than $28 million from new, existing and insider investors, including Boxer Capital Management, Coastlands Capital and Vivo Capital. The offering comprised 928,333 units of common stock and warrants priced above market under Nasdaq rules, resulting in gross proceeds of approximately $6.03 million in the initial tranche. The oversubscription highlights strong demand among institutional and strategic investors for Clene’s late clinical–stage neurodegenerative pipeline.
2. Initial Tranche Funds Operations into Third Quarter of 2026
The initial financing tranche of roughly $6 million is expected to provide a cash runway through the third quarter of 2026, enabling Clene to advance its planned New Drug Application (NDA) acceptance decision by the FDA for CNM-Au8 in amyotrophic lateral sclerosis. Management indicated that these funds will cover key regulatory milestones, manufacturing scale-up and biomarker analyses ahead of the anticipated FDA Prescription Drug User Fee Act (PDUFA) date announcement in early 2026.
3. Contingent Financing Tranches Linked to FDA Decisions
Under the terms of the securities purchase agreements, two additional financing tranches totaling more than $22 million are contingent upon (i) FDA acceptance of the CNM-Au8 NDA and (ii) FDA approval of the NDA. The second tranche would follow NDA acceptance, while the third tranche is structured to close upon formal FDA approval, providing incremental capital for potential U.S. commercialization efforts and supporting the transition from clinical development to market launch.
4. Investor Syndicate and Warrant Structure Provide Upside
Each unit in the offering included Series A and Series B warrants exercisable for common stock. Series A warrants, exercisable immediately, carry an initial strike price with an automatic increase tied to the timing of the PDUFA announcement, representing potential additional proceeds of approximately $6.7 million upon full exercise. Series B warrants, also immediately exercisable, feature a graduated strike price adjustment based on the timing of FDA approval and post-approval volume-weighted average share prices, with potential proceeds of around $15.6 million. Clene retains the right to redeem unexercised warrants for $0.01 per share under specified conditions, enhancing capital efficiency and limiting dilution risk.